CN101578294A - 丙型肝炎病毒抑制剂 - Google Patents

丙型肝炎病毒抑制剂 Download PDF

Info

Publication number
CN101578294A
CN101578294A CNA2007800490456A CN200780049045A CN101578294A CN 101578294 A CN101578294 A CN 101578294A CN A2007800490456 A CNA2007800490456 A CN A2007800490456A CN 200780049045 A CN200780049045 A CN 200780049045A CN 101578294 A CN101578294 A CN 101578294A
Authority
CN
China
Prior art keywords
alkyl
compound
hcv
mmol
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800490456A
Other languages
English (en)
Chinese (zh)
Inventor
S·丹德里
P·M·斯科拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101578294A publication Critical patent/CN101578294A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CNA2007800490456A 2006-11-01 2007-10-31 丙型肝炎病毒抑制剂 Pending CN101578294A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86385706P 2006-11-01 2006-11-01
US60/863,857 2006-11-01

Publications (1)

Publication Number Publication Date
CN101578294A true CN101578294A (zh) 2009-11-11

Family

ID=39365223

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800490456A Pending CN101578294A (zh) 2006-11-01 2007-10-31 丙型肝炎病毒抑制剂

Country Status (6)

Country Link
US (1) US20080107623A1 (enExample)
EP (1) EP2086994B1 (enExample)
JP (1) JP2010508362A (enExample)
CN (1) CN101578294A (enExample)
NO (1) NO20091706L (enExample)
WO (1) WO2008057875A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
SG174809A1 (en) * 2007-05-03 2011-10-28 Intermune Inc Macrocyclic compounds useful as inhibitors of hepatitis c virus
AU2008251425A1 (en) 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
WO2009005690A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
AR070413A1 (es) * 2008-02-04 2010-04-07 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de proteasa de serina
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
WO2010135748A1 (en) * 2009-05-22 2010-11-25 Sequoia Pharmaceuticals Inc. Bimacrocyclic hcv ns3 protease inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2011049908A2 (en) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
KR20130036201A (ko) * 2010-02-22 2013-04-11 메르크 파텐트 게엠베하 헤타릴아미노나프티리딘
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN103396351B (zh) * 2013-08-09 2015-10-21 山东大学 吡咯烷类Bcl-2蛋白小分子抑制剂化合物及其制备、药物组合物与制药用途
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
HRP20231163T1 (hr) 2015-07-31 2024-03-15 The Johns Hopkins University Prolijekovi glutaminskih analoga
US11185534B2 (en) 2017-02-01 2021-11-30 The Johns Hopkins University Prodrugs of glutamine analogs
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP1629000B1 (en) * 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
AU2004231987C1 (en) * 2003-04-18 2010-09-30 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CA2549851C (en) * 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
WO2005090383A2 (en) * 2004-03-15 2005-09-29 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections
JP2008517896A (ja) * 2004-10-21 2008-05-29 ファイザー・インク Ｃ型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
TW200738742A (en) * 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
WO2008022006A2 (en) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis c virus protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors

Also Published As

Publication number Publication date
US20080107623A1 (en) 2008-05-08
EP2086994B1 (en) 2014-11-26
EP2086994A2 (en) 2009-08-12
WO2008057875A2 (en) 2008-05-15
WO2008057875A3 (en) 2008-07-31
JP2010508362A (ja) 2010-03-18
NO20091706L (no) 2009-07-21

Similar Documents

Publication Publication Date Title
US8343477B2 (en) Inhibitors of hepatitis C virus
EP2086994B1 (en) Inhibitors of hepatitis c virus
EP1951743B1 (en) Hepatitis c virus inhibitors
CN101583611A (zh) 丙型肝炎病毒抑制剂
EP2049474B1 (en) Hepatitis c virus inhibitors
EP1684787B1 (en) Hepatitis c virus inhibitors
EP1687018B1 (en) Hepatitis c virus inhibitors
EP1945641B1 (en) Hepatitis c virus inhibitors
CN101541784B (zh) 丙型肝炎病毒抑制剂
EP2086995B1 (en) Hepatitis c virus inhibitors
EP2300490B1 (en) Hepatitis c virus inhibitors
EP2086980B1 (en) Macrocyclic peptides as hepatitis c virus inhibitors
EP2265606B1 (en) Hepatitis c virus inhibitors
ES2574133T3 (es) Inhibidores del virus de la hepatitis C
ES2650223T3 (es) Tripéptidos que incorporan deuterio como inhibidores del virus de la hepatitis C
WO2004032827A2 (en) Hepatitis c virus inhibitors
CN101652383B (zh) 丙型肝炎病毒抑制剂
CN101568543B (zh) 大环肽作为丙型肝炎病毒抑制剂
CN101568336B (zh) 大环肽在制备丙型肝炎病毒抑制剂中的用途
HK1128131B (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20091111